pCR favorably predicts RFS in real-world study of early breast cancer

  • LeVasseur N & al.
  • J Cancer Res Clin Oncol
  • 18 Nov 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pathologic complete response (pCR) is a favorable prognostic indicator of relapse-free survival (RFS) in a real-world study of early breast cancer (eBCa), even triple-negative breast cancer (TNBC).

Why this matters

  • This is the first real-world population-based study of its kind.
  • Findings suggest that pCR is a valid surrogate outcome in clinical trials, as well as population-based settings.

Study design

  • Retrospective population-based analysis of stage I-III BCa in the British Columbia Breast Cancer Outcomes Unit database, 2005-2010 (n=267).
  • pCR was compared with residual invasive disease in the breast/axillary lymph nodes (RD).
  • Primary outcome: RFS.
  • Funding: None.

Key results

  • Median follow-up: 7.4 years.
  • 28% of patients achieved pCR; 72% had RD.
  • 5-year RFS was 55% higher in the pCR group (84% vs 70% in the RD group; HR, 0.45; P=.01).
  • 5-year breast cancer-specific survival (BCSS) was 61% higher in the pCR group (90% vs 77%; HR, 0.39; P=.01).
  • In multivariate analysis, pCR was associated with better RFS (HR, 0.39; P<.01 and bcss p=".015).</li">
  • In subgroup analysis, patients with TNBC (but not those with other subtypes) who achieved pCR had improved RFS (HR, 0.26; P=.02) and nonstatistically better BCSS (HR, 0.35; P=.09).

Limitations

  • Retrospective, observational design.